Microbiome-based therapy shows promise in solid tumors, including ccRCC
June 17th 2024"The positive trends emerging from the ongoing phase 1 trial of BMC128, particularly in combination with nivolumab, underscore the transformative potential of microbiome-based therapeutics in oncology,” says Gal Markel, MD, PhD, MBA.
Disitamab vedotin plus toripalimab shows early efficacy in HER2-positive MIBC
June 14th 2024Disitamab vedotin is a novel humanized anti-HER2 antibody-drug conjugate that previously demonstrated encouraging anti-tumor activity in combination with toripalimab in patients with metastatic urothelial carcinoma.
Studies show low urinary bladder interference on flotufolastat F 18 scans
June 11th 2024“The ability to gather actionable information from PSMA PET scans is important for physicians to make informed decisions about patient management for men with prostate cancer,” says Eugene Teoh, MBBS, MRCP, FRCR, DPhil.
Study reinforces value of precision medicine in prostate cancer
June 6th 2024"Ensuring equal access to genomic tumor testing and precision medicine treatments may be a viable strategy to help close the well-described gaps in prostate cancer outcomes between Black and White men," says Luca F. Valle, MD.
FDA clears labeling revision on da Vinci X and Xi for radical prostatectomy
June 5th 2024The change was made following the submission of a real-world evidence study showing that 5- to 10-year overall survival following robot-assisted radical prostatectomy was comparable to that of non-robotic radical prostatectomy.
PRO data complement efficacy, safety data from EV-302 trial in urothelial cancer
June 3rd 2024“The PRO data presented here complements the published clinical efficacy and safety data, add the patient's voice, and support the use of EV/pembro for patients with locally advanced/metastatic urothelial cancer," says Shilpa Gupta, MD.
Avelumab plus cisplatin-based chemotherapy results in high survival in MIUC
June 1st 2024"In the cisplatin-ineligible cohorts, we showed that high event-free survival and overall survival rates can be achieved at 12 and 36 months in patients treated with neoadjuvant avelumab in combination with cisplatin-based chemotherapy," says Jeremy Blanc, MD.